chrisvoncsefalvay/vaers-outcomes huggingface dataset:
blurred vision; calf redness pain; calf redness; rash torso arms legs; Itchiness eyes; This was a booster after 2 earlier moderna shots; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 63-year-old patient received BNT162b2 (BNT162B2), on 30Nov2021 at 14:00 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 63 years intramuscular, in left arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Moderna (DOSE 1, SINGLE), for COVID-19 immunisation; Moderna (DOSE 2, SINGLE), for COVID-19 immunisation. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (disability) with onset 30Nov2021 at 14:00, outcome "recovered", described as "This was a booster after 2 earlier moderna shots"; EYE PRURITUS (disability) with onset 02Dec2021, outcome "recovered", described as "Itchiness eyes"; RASH (disability) with onset 02Dec2021, outcome "recovered", described as "rash torso arms legs"; ERYTHEMA (disability) with onset 06Dec2021, outcome "recovered", described as "calf redness"; PAIN IN EXTREMITY (disability) with onset 06Dec2021, outcome "recovered", described as "calf redness pain"; VISION BLURRED (disability), outcome "recovered", described as "blurred vision". The events "rash torso arms legs", "itchiness eyes", "blurred vision", "calf redness pain" and "calf redness" required physician office visit. The patient underwent the following laboratory tests and procedures: Complement analysis: (06Dec2021) Normal, notes: Normal; Complement factor C1: (06Dec2021) Normal, notes: Normal; Complement factor C4: (06Dec2021) Normal, notes: Normal; Full blood count: (10Dec2021) Normal, notes: Normal; Metabolic function test: (10Dec2021) Normal, notes: Normal; Multisystem inflammatory syndrome in children: (06Dec2021) Normal, notes: Normal. Therapeutic measures were taken as a result of rash, eye pruritus, vision blurred. Therapeutic measures were not taken as a result of pain in extremity, erythema which included Antihistamine for 2-3 weeks. Clinical course: Vaccination Facility Type was Hospital.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
lethargic for 2 days;spiked temp of 105, APAP given every 4hrs & MD visit made;leg had localize reaction;denies any seizure;
Extreme exhaustion, soreness and elevated temp. Shot was Saturday it is now Tuesday morning not enough energy to shower
I woke up the morning after the vaccine with a gnawing pain in my left upper arm and shoulder.  Interestingly enough it was in the left arm.  I had my vaccine in my right arm.  I suffered through this for 3 weeks, thinking it surely would go away, but finally went in to see NPA.  She gave me a cortisone shot in my left shoulder.  It took a couple of days, but the pain started to get better.  I do not have full outward motion like before, but I do not suffer from that gnawing pain day and night like I did for 3 weeks.
I started feeling poorly on 11/26/22 and took my temperature, it was 101.5F. I felt like I had the flu. I awoke with body aches, still feeling bad, my temperature did come down some. I felt nauseous and more like I had the flu or bad a bad cold. I use my home COVID-19 test that came back positive but waited until later in the day to take a second test. The second test also showed positive, so I called my doctor and had a telehealth visit and was prescribed PAXLOVID, after three days I could eat. After the five days of PAXLOVID, I felt better but the fatigue lasted for three weeks, once it was gone, I have been feeling more like myself.
Patient received 1st dose of SHINGRIX vaccine in the pharmacy at 12:15. 10 minutes later, she reported tingling in her legs and light-headedness. Husband was present. EMS was called and took her to the hospital. ED Note: This is a 69-year-old female presents emergency department with altered mental status. She received a vaccination in the office and around noon she started to feel funny. She had a staring episode where she could not speak that lasted a period of time. She also admits to blurred vision that also resolved. She feels at her normal mental baseline currently and denies any complaints. She denies lightheadedness, dizziness, sense of spinning. She denies facial droop, numbness, focal weakness. She is feeling generally fatigued. She had similar symptoms last time she had a seizure. Her typical seizures are staring episodes which she feels similar today. She takes KEPPRA and is compliant with that medication. She did admit to a mild headache that resolved gradual onset similar to prior headaches. She denies any neck pain or back pain or fever.  She denies fall or injury. She denies syncope. Amp of D50 given. Plan to have patient orally eat after CT brain performed. She denies any chest pain or shortness of breath in the ED.
has broken out with herpes on the back of her leg and it is currently red and blistery; has broken out with herpes on the back of her leg and it is currently red and blistery; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age received bnt162b2 (BNT162B2 reported as PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration on 08Apr2021 (Batch/Lot number was not reported) as a single dose for covid-19 immunization. Medical history includes shingles break out. The patient's concomitant medications were not reported. The patient previously took valaciclovir hydrochloride (VALTREX S) from an unspecified date to unspecified date in 2021 at three times a day for shingles break out. The patient inquired if there is an interaction between the Covid vaccine and Valtrex. The patient reported that before she received her first vaccine dose, she experienced a shingles breakout and was taking Valtrex 3 times per day. She mentioned that she received her first vaccine dose on 08Apr2021 and now, she is experiencing herpes breakout on her leg and needs another prescription for Valtrex. She inquired if this would interact with the vaccine as her second vaccine dose is scheduled for 29Apr2021. The patient further mentioned that she had to postpone the first dose of the Pfizer COVID vaccine because of shingles. She stated that she was taking Valtrex three times a day and that the Valtrex package said do not take with any vaccine or immunization so she rescheduled the first dose of the Pfizer COVID vaccine because Valtrex should not be taken with a vaccine. She waited a week after completing the Valtrex and got the first Pfizer COVID vaccine on 08Apr2021. She reported that she has broken out with herpes on the back of her leg and it is currently red and blistery on Apr2021. She added that she has had this before and she guesses she needs to talk to her dermatologist, but figures Pfizer know more about the interactions than the dermatologist does. She further added that usually when she has a herpes breakout that the dermatologist either does a cortisone shot into the breakout or she takes Valtrex, but she saw that it is not good to mix the Valtrex with immunizations. She mentioned that this current breakout is not related to the Pfizer COVID vaccine and she declines to complete the report. The adverse events were considered as non-serious. The outcome of the events was not recovered.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.; Sender's Comments: Based on the information provided by the reporter, it appears unlikely that subject vaccine contributed to the events of shingles and condition aggrevated.  The reported events likely represent intercurrent medical conditions.
my joints starting aching; my muscles in my back and hubs starting aching; rarely ever have a headache by I got a severe one; This case was reported by a consumer via call center representative and described the occurrence of joint pain in a 70-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On 11th March 2020, the patient received1st dose of Shingrix. On 18th March 2020, 7 days after receiving Shingrix, the patient experienced joint pain, muscular back pain and headache. On an unknown date, the outcome of the joint pain, muscular back pain and headache were unknown.   It was unknown if the reporter considered the joint pain, muscular back pain and headache to be related to Shingrix.  Additional details were provided as follows: On 18th March 2020, the patient joints and muscles in back and hubs started aching. The patient rarely had headache but he/she got a severe headache after Shingrix.
A 68 year old female patient received Fluzone (lot number U2243AA) on the first week of October 2006. Shortly after, the same day, she experienced upper arm discomfort and lower leg weakness. No corrective treatment was reported. The patient had recovered. No concomitant vaccines were reported. The patient had history of "RA" (probably Rheumatoid Arthritis). The patient had "many" previous doses of Fluzone with no reported symptoms. Follow-up information received on 11 December 2006. The patient was taking Plaquenil, Coumadin, Synthroid, Fosamax, Zetia, Wellbutrin, and HCTZ at the time of vaccination in October 2006. She had not received any other vaccinations within four weeks of that vaccination. No relevant diagnostic tests/laboratory data were performed. No further information is expected.
the vaccine was administered after expiration.; No adverse event; This spontaneous report as received from an other health professional (Nurse) referring to a patient of unknown age. The patient concomitant therapies, medical history, concurrent conditions, drug reactions and allergies were not reported.  On 15-NOV-2021, the patient was vaccinated with the first dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (Lot # S036662, expiration date: 14-NOV-2021) 0.5 milliliter for prophylaxis (expired product administered). It was reported that no adverse event occurred. At the time of the report, the outcome of the event was not reported.  The causal relationship between the event and the suspect vaccine was not reported.
This initial spontaneous report was received on 15-DEC-2017 from a lawyer regarding a case in litigation and refers to a male patient of unknown age. Medical history, concurrent conditions, and concomitant medications were not provided. The patient was inoculated with ZOSTAVAX on or about 30-DEC-2011, administered (by an unspecified person) at a clinic as recommended for routine adult health maintenance and for the prevention of shingles (dose, route of administration, site of administration and lot # were not provided). The vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of shingles. On or about 11-DEC-2016, the patient was treated at the hospital, for the onset of a blistery rash accompanied by weakened immune symptoms, which was diagnosed as severe herpes zoster, or shingles. On or about 18-DEC-2016, the patient sought subsequent treatment at the hospital for worsening symptoms of shingles, which was diagnosed as polyneuropathy compounded upon Herpes zoster. On or about 19-DEC-2016, the male patient was treated by a family nurse practitioner at a medical facility for ongoing and worsening symptoms, diagnosed as zoster infections and post-herpetic neuralgia. The patient has been prescribed acyclovir and tramadol injections for management of his painful symptoms. As a direct and proximate result of these malfunctions, the patient has suffered and will continue to suffer significant medical expenses, lost wages, pain and suffering, and other damages. The outcome of the events was not resolved.  The lawyer felt the events were related to ZOSTAVAX. Upon medical review, the event of Sought subsequent treatment for worsening symptoms of shingles, which was diagnosed as polyneuropathy compounded upon Herpes zoster was considered to be a medically significant event. Additional information has been requested.
12/18 vaccine received 12/19- awoke with left side arm pit swelling 12/23-sore throat 12/24 swollen lymph node in throat 12/26 gone upon awakening 12/26 6-7pm acute onset right hand swelling hot/red inflamed from palm to wrist 12/28-gone upon awakening 12/28 12 P acute onset left hand, same as above 12/30  gone upon awakening today
FLU-LIKE SYMPTOMS, LIKE A FEVER, ACHES,SLEEPLESSNESS, CHILLS,FATIGUE
A spontaneous report was received from a physical therapist concerning a 55-year-old, female patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced anaphylaxis, felt warm/feeling hot, breathing problem/dyspnea, tired for the next couple of days/fatigue, increased heart rate, abnormal blood pressure. The patient's medical history was not provided. No relevant concomitant medications were provided. On 31 Dec 2020, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Lot number: 011J20A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the patient developed anaphylaxis within seven to eight minutes after vaccination and was hospitalized. First, she felt warm and removed her sweater. Very rapidly, she had problems with breathing. She was discharged after six hours. She only had one rebound reaction. She was sent home after her heart rate and blood pressure were back to normal. She was tired for the next couple of days. Treatment medications included two epinephrine injection in the right thigh and IV diphenhydramine in the left arm. She reported that they gave her 15 litres of oxygen and another medication, which she cannot recall the name. Action taken with mRNA-1273 in response to the events was not applicable. The outcome of the reported events were considered as resolved. Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
During the observation period, vaccine recipient began complaining of his heart racing.  RN observed flushing to patient head and neck.  HR of 64.  Patient taken to the ED for further evaluation and monitoring.
not feeling well; Blood pressure went up/Blood pressure was high/At nighttime, his blood pressure goes up a little bit; Headache; Feeling a little feverish/Feels feverish once in a while; This spontaneous case was reported by a patient and describes the occurrence of MALAISE (not feeling well), HYPERTENSION (Blood pressure went up/Blood pressure was high/At nighttime, his blood pressure goes up a little bit), HEADACHE (Headache) and PYREXIA (Feeling a little feverish/Feels feverish once in a while) in a 77-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 056A22A, 029D21A, 010A21A and 010M20A) for COVID-19 vaccination.     No allergies were reported.  The patient's past medical history included Heart attack and Stent placement in 2009. Concurrent medical conditions included Hypertension. Concomitant products included METOPROLOL for Blood pressure high, ROSUVASTATIN and CURCUMA LONGA (TURMERIC [CURCUMA LONGA]) for an unknown indication.   On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 21-Jun-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MALAISE (not feeling well), HYPERTENSION (Blood pressure went up/Blood pressure was high/At nighttime, his blood pressure goes up a little bit), HEADACHE (Headache) and PYREXIA (Feeling a little feverish/Feels feverish once in a while). The patient was treated with PARACETAMOL (TYLENOL) for Feverish and Headache, at an unspecified dose and frequency and METOPROLOL for Blood pressure high, at an unspecified dose and frequency. At the time of the report, MALAISE (not feeling well), HYPERTENSION (Blood pressure went up/Blood pressure was high/At nighttime, his blood pressure goes up a little bit), HEADACHE (Headache) and PYREXIA (Feeling a little feverish/Feels feverish once in a while) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: High. On an unknown date, SARS-CoV-2 test: (Negative) Negative.         Patient never had diagnosed with COVID. It was reported that patient went to the ER right away and they increase the dose of metoprolol to calm his blood pressure. Patient used to take metoprolol  25mg, 1 tablet in the morning and 1 tablet in the evening and now it is metoprolol 25mg 2 tablets in the morning and 2 tablets in evening.
fever; chills; This is a spontaneous report from a contactable other healthcare professional (patient).   A 39-year-old male patient received bnt162b2 (BNT162B2), via an unspecified route of administration, administered in Arm Left on 01Mar2021 12:00 (Batch/Lot number was not reported) as DOSE 2, SINGLE for covid-19 immunisation.  The patient medical history was not reported. The patient did not have COVID-19 prior the vaccination. Concomitant medication included paracetamol (TYLENOL) taken for an unspecified indication, start and stop date were not reported.  On 01Mar2021 21:00, the patient experienced chills and fever. The outcome of the events was not recovered.  No treatment was received for the events. The patient was not tested for COVID-19 post vaccination.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Slightly itchy; Red circle where the shot was given, redness kind of spread, getting bigger; This spontaneous case was reported by a health care professional and describes the occurrence of VACCINATION SITE PRURITUS (Slightly itchy) and VACCINATION SITE ERYTHEMA (Red circle where the shot was given, redness kind of spread, getting bigger) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history). Concomitant products included CETIRIZINE HYDROCHLORIDE (ZYRTEC ALLERGY), LEVOTHYROXINE SODIUM (LEVOTHYROX), CETIRIZINE, LEVOTHYROXINE, OMEPRAZOLE, FLUVASTATIN, FLUOXETINE and ZOLPIDEM for an unknown indication.    On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (Slightly itchy) and VACCINATION SITE ERYTHEMA (Red circle where the shot was given, redness kind of spread, getting bigger). On 07-Jan-2021, VACCINATION SITE PRURITUS (Slightly itchy) and VACCINATION SITE ERYTHEMA (Red circle where the shot was given, redness kind of spread, getting bigger) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
I went in to get the shot after I started to feel lightheaded. The staff advised that I sit down in the waiting room. They cleared me to go home. When I got home I just felt sick for the next ten days. Thereafter I waited until the seventh day I spoke to a nurse she said if I didn't improve within the next few days then I needed to seek medical attention.
Hematuria (literally clots of blood and urine was very red/pink). Last from 10 September 2021 to 17 September 2021. Self treated with cranberry juice, vitamin C, 1 gallons of water minimum daily, frequent urination and time. Eventually improved on its own. No medical treatment was administered.
Right thigh Kw/inflammation, hardness, erythema slightly tender circumscribed lesion about 2 1/2 inches in diameter.
Lump in left axillary. Sensitivity to cold. Pain radiating in left arm. Chronic pain in left breast and under left arm.  Per 60 day follw up: pain neurological symptoms including burning, tingling, sensations throughout body. Still have lump from flushot and presently under dis care for possible auto-immune damage and neurological damage. Thank you for your help and consideration : )
I started with itching and woke up this morning with a rash and itching on my face, chest neck, upper arms, and upper back.
Arm has a knot , red swollen , redness measured 4"  on 11/17/21  Measured 7" on 11/18/21 Not sure what if anything needs to be done
Extremely sore arm at the injection site for approximately 72 hours. So much so that it was difficult to sleep at night.
Mild cold symptoms; Mild sore throat; This spontaneous case was reported by a consumer and describes the occurrence of NASOPHARYNGITIS (Mild cold symptoms) and OROPHARYNGEAL PAIN (Mild sore throat) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).   On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced NASOPHARYNGITIS (Mild cold symptoms) and OROPHARYNGEAL PAIN (Mild sore throat). At the time of the report, NASOPHARYNGITIS (Mild cold symptoms) and OROPHARYNGEAL PAIN (Mild sore throat) outcome was unknown.
Pt here at 2-month well-baby check. Rotavirus vaccine was given to pt, followed by immunizations. Pt broke out in hives on legs, torso and face within 10 minutes. No signs of respiratory distress. Pt was monitored here for 30+ minutes, no further complications.
Discharge Provider: DO Primary Care Provider at Discharge: MD  Admission Date: 8/31/2022 Discharge Date: 9/2/2022  HOSPITAL COURSE: The patient is a 70 y.o. female with past medical history significant for HFpEF, Afib (on eliquis), T2DM (requiring insulin), CKD IV, hypertension, and Von Willebrand disease, who presented to the ED with a chief complaint of cough and shortness of breath. Upon arrival to the ED patient was hypertensive of 179/64, remainder of vitals were stable. Saturations were 87% on room air with improvement to the mid 90s following 2 L nasal cannula. COVID-19 was noted to be positive. CXR revealed moderate pulmonary edema with CHF expected. While in the ED the patient did receive 1 L of normal saline as well as a 1-time dose of IV Lasix 40 mg. The patient was admitted to hospital medicine for further evaluation and management.    Patient quickly improved with wean from oxygen. She remained on decadron while admitted, due to hx of DM and improvement in respiratory status, decadron was not continued on discharge. Patient aware to monitor blood glucose and blood pressure closely at home. He was discharged home in stable condition.
I started getting symptoms of sore throat, chills, and cough. I had a doctors appointment that morning and before I went in I took an at home COVID-19 test that was positive. Then I did a telehealth visit. I also experienced some congestion and headache. I was prescribed Paxlovid. By 4/28/2022 my symptoms dissipated. I am still showing positive.